MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/16078454.2022.2121900

Медицинская библиотека · Hematology (Amsterdam, Netherlands) · 2022

Efficacy of maintenance treatment in patients with multiple myeloma: a systematic review and network meta-analysis.

Zhi Yongjin, Bao Shuojing, Mao Jingcheng, Chai Gufan, Zhu Jianfeng, Liu Chengjiang, Chen Xi

СтатьяСистематический обзорNetwork Meta-AnalysisПеревод в очереди

Аннотация

BACKGROUND

Despite conspicuous advances in innovating novel drugs and combination regimens in multiple myeloma (MM) in recent decades, the most appropriate maintenance regimens after inductive therapy are still controversial and opaque.

OBJECTIVE

We aimed to identify the most effective maintenance treatment for newly diagnosed multiple myeloma (NDMM) patients via network meta-analysis.

METHOD: We searched PubMed, Embase, Cochrane Library, Scopus, and Google Scholars from inception to April, 2022. Odds ratios (ORs) were generated for dichotomous variants. The primary endpoint was overall survival (OS).

RESULTS

Eventually a total of 19 trials, including 11 treatments and 8337 patients, were included in this analysis. For OS, lenalidomide (OR ranged from 1.61 to 1.99) and daratumumab (OR ranged from 1.83 to 2.41) showed significant efficacy over placebo. Maintenance therapy comprising lenalidomide-carfilzomib (OR ranged from 3.19 to 6.95), lenalidomide-prednisone (OR ranged from 2.62 to 4.44), bortezomib-thalidomide (OR ranged from 2.48 to 3.64), daratumumab (OR ranged from 2.0 to 2.98), lenalidomide (OR ranged from 1.4 to 3.19), ixazomib (OR ranged from 1.36 to 2.05), thalidomide (OR ranged from 1.5 to 1.86) demonstrated significant effects in prolonging PFS compared with placebo; Among the efficient therapies, lenalidomide-carfilzomib was significantly superior to lenalidomide (OR ranged from 2.18 to 2.20), daratumumab (OR ranged from 1.49 to 2.66) and ixazomib (OR ranged from 2.75 to 3.57).

CONCLUSION

Considering OS and PFS, lenalidomide-carfilzomib should be recommended as the best therapy. In clinical practice, this must be weighed against the increased risk of adverse events and financial burden. However, more head-to-head studies are needed to confirm these findings.

Для цитирования: Zhi Yongjin, Bao Shuojing, Mao Jingcheng, Chai Gufan, Zhu Jianfeng, Liu Chengjiang, Chen Xi. Efficacy of maintenance treatment in patients with multiple myeloma: a systematic review and network meta-analysis.. Hematology (Amsterdam, Netherlands). 2022. DOI: 10.1080/16078454.2022.2121900.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.